<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>02/03/2024 14:42:35</Export_date>
    <Internal_Number>13645043
    </Internal_Number>
    <TrialID>DRKS00023540
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Effects of MR-guided focused ultrasound subthalamotomy on non-motor and motor symptoms of Parkinson’s disease patients with motor fluctuations – a pilot study.  


    </Public_title>
    <Scientific_title>Effects of MR-guided focused ultrasound subthalamotomy on non-motor and motor symptoms of Parkinson’s disease patients with motor fluctuations – a pilot study.  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Schleswig-Holstein, Campus Kiel
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201130
    </Date_registration3>
    <Date_registration>30/11/2020
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00023540
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/12/2020
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: N/A: single arm study; Masking: Open (masking not used); Control: uncontrolled; Assignment: single; Study design purpose: treatment 
    </Study_design>
    <Phase>4
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Steffen
    </Contact_Firstname>
    <Contact_Lastname>Paschen
    </Contact_Lastname>
    <Contact_Address>Arnold-Heller-Straße 3, Haus 41
    </Contact_Address>
    <Contact_Email>steffen.paschen@uksh.de
    </Contact_Email>
    <Contact_Tel>043150023956
    </Contact_Tel>
    <Contact_Affiliation>Klinik für Neurologie, UKSH, Campus Kiel
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. diagnosis of PD according to MDS diagnosis criteria for = 4 years&lt;br&gt;2. disabling motor fluctuations despite optimized medical treatment&lt;br&gt;3. a levodopa response of = 30% in the standardized levodopa-test &lt;br&gt;4. tremor of any type
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. neurosurgical contraindications (e.g. brain atrophy, history of abnormal bleeding, cerebro-vascular and cerebro- inflammatory disease)&lt;br&gt;2. standard MRI-contraindications such as non-MRI compatible implanted metallic devices including cardiac pacemakers&lt;br&gt;3. severe depression, dementia or unstable psychiatric disease&lt;br&gt;4. general contraindications (e.g. unstable cardiac status or arterial hypertension, substance abuse)
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: unilateral MRgFUS subthalamotomy of the more affected body side
    </Intervention>
    <Primary_outcome>Effects on non-motor and motor symptoms in PD. All endpoints will be exploratory. 
    </Primary_outcome>
    <Secondary_outcome>Effects on non-motor and motor symptoms in PD. All endpoints will be exploratory (for detailed description see study protocol). 
    </Secondary_outcome>
    <Source_Support>ParkinsonFonds Deutschland gGmbH
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>10/11/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethikkomm@email.uni-kiel.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Medizinischen Fakultät der Christian-Albrechts-Universität zu Kiel
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-431-50014191
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethikkomm@email.uni-kiel.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00023540#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:42:35</Export_date>
    <Internal_Number>12917981
    </Internal_Number>
    <TrialID>NCT04250376
    </TrialID>
    <Last_Refreshed_on>3 April 2023
    </Last_Refreshed_on>
    <Public_title>The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias
    </Public_title>
    <Scientific_title>The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Neurological Associates of West Los Angeles
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200129
    </Date_registration3>
    <Date_registration>29/01/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04250376
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>45 Years
    </Inclusion_agemin>
    <Inclusion_agemax>93 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 27, 2017
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Sheldon E Jordan, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Neurology Management Associates
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  CDR stage of at least 0.5 (mild cognitive impairment)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least one pathognomic imaging biomarker of a neurodegenerative process.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive decline clearly related to an acute illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects unable to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with scalp rash or open wounds on the scalp (for example from treatment of&#x0D;&lt;br&gt;             squamous cell cancer)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Advanced terminal illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Advanced kidney, pulmonary, cardiac or liver failure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who would not be able to lay down without excessive movement in a calm&#x0D;&lt;br&gt;             environment sufficiently long enough to be able to achieve sleep&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with major depressive disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with vascular causes of dementia&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Mild Cognitive Impairment;Mild Dementia;Parkinson Disease;Alzheimer Disease
    </Condition>
    <Intervention>Device: Focused Transcranial Ultrasound
    </Intervention>
    <Primary_outcome>Quick Dementia Rating Scale
    </Primary_outcome>
    <Secondary_outcome>Repeatable Battery Assessment for Neuropsychological Status (RBANS);Repeatable Battery Assessment for Neuropsychological Status (RBANS);Montreal Cognitive Assessment (MoCA);Montreal Cognitive Assessment (MoCA);Quick Dementia Rating Scale (QDRS)
    </Secondary_outcome>
    <Secondary_ID>32222-1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>
</Trials_downloaded_from_ICTRP>